ArticleJournal of cellular and molecular medicine2025
AdipoRon Mitigates Anxiety and Depression Symptoms in Chronic Sleep-Restricted Mice via Modulation of Neuroinflammatory Responses.
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Therapeutic potential of AdipoRon in cognitive, depressive, and anxiety disorders: a systematic review and meta-analysis.Molecular brain · 2026Pooled it
- Kynurenine Pathway Metabolites as Mediators of Exercise-Induced Mood Enhancement, Fatigue Resistance, and Neuroprotection.International journal of molecular sciences · 2025Review
- AdipoRon Mitigates Anxiety and Depression Symptoms in Chronic Sleep-Restricted Mice via Modulation of Neuroinflammatory Responses.Journal of cellular and molecular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The contemporary lifestyle has resulted in an epidemic of chronic sleep restriction (SR), which has emerged as a substantial contributor to mood disorders, particularly anxiety and depression. This study examined the effectiveness of AdipoRon (Adipo), a synthetic adiponectin agonist, in mitigating anxious behaviours and depression-like symptoms in a chronic SR mice model. Forty male Swiss albino mice were divided into four groups: wide platform (WP), SR, SR + melatonin (Mel), and SR + Adipo. Over 21 days, the animals underwent a modified multiple-platform technique to induce SR, followed by daily intranasal treatments. The open field test and elevated plus maze were conducted to assess anxiety-related behaviours, while the forced swimming test and sucrose splash test were used to assess depressive symptoms. Serum corticosterone concentrations, a marker of microglia activation, and pro-inflammatory mediators (NF-кB and IL-1β) in the prefrontal cortex (PFC) were also examined. Intranasal administration of Adipo markedly decreased anxiety-like behaviours, despair, and apathy in sleep-restricted mice compared to the SR group. Adipo therapy also reduced pro-inflammatory proteins and ionised calcium-binding adaptor molecule-1 (Iba-1)-positive cells in the PFC and restored serum corticosterone levels. These outcomes emphasise the therapeutic benefit of Adipo as an alternative therapy for mood disorders associated with SR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.